CSRO Policy Update, August 2018, Issue 7
As the last of the 2018 regular sessions wind down across the states, CSRO is happy to report that the year to date has been marked by a number of successes on the patient access front. As
CSRO Discusses Part B and D with CMS
Members of CSRO’s executive board recently met with CMS to discuss Part B and D drug pricing. Doctors Michael Schweitz, Madelaine Feldman, Greg Schimizzi traveled to D.C. to present CSRO’s feedback on recent proposals and provide rheumatology’s perspective on the programs.